Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1990 1
1993 1
2004 1
2005 1
2007 3
2008 3
2010 1
2011 5
2012 5
2013 5
2014 2
2018 2
2019 2
2020 1
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy JS, Jahreis A, Genovese MC, Mozaffarian N, Landewé RBM, Bae SC, Keystone EC, Nash P. Combe B, et al. Among authors: baraf hsb. Ann Rheum Dis. 2021 Jul;80(7):848-858. doi: 10.1136/annrheumdis-2020-219214. Epub 2021 Jan 27. Ann Rheum Dis. 2021. PMID: 33504485 Free PMC article. Clinical Trial.
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA. Sundy JS, et al. Among authors: baraf hs. JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169. JAMA. 2011. PMID: 21846852 Clinical Trial.
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
Baraf HSB, Khanna PP, Kivitz AJ, Strand V, Choi HK, Terkeltaub R, Dalbeth N, DeHaan W, Azeem R, Traber PG, Keenan RT. Baraf HSB, et al. Rheumatology (Oxford). 2024 Apr 2;63(4):1058-1067. doi: 10.1093/rheumatology/kead333. Rheumatology (Oxford). 2024. PMID: 37449908 Free PMC article. Clinical Trial.
2011 recommendations for the diagnosis and management of gout and hyperuricemia.
Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F, Harford R, Lieberman JA 3rd, Mandel DR, Mandelbrot DA, McClain BP, Mizuno E, Morton AH, Mount DB, Pope RS, Rosenthal KG, Setoodeh K, Skosey JL, Edwards NL. Hamburger M, et al. Among authors: baraf hs. Phys Sportsmed. 2011 Nov;39(4):98-123. doi: 10.3810/psm.2011.11.1946. Phys Sportsmed. 2011. PMID: 22293773 Review.
Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.
Botson JK, Baraf HSB, Keenan RT, Albert J, Masri KR, Peterson J, Yung C, Freyne B, Amin M, Abdellatif A, Soloman N, Edwards NL, Strand V. Botson JK, et al. Among authors: baraf hsb. Curr Rheumatol Rep. 2022 Jan;24(1):12-19. doi: 10.1007/s11926-022-01055-9. Epub 2022 Feb 15. Curr Rheumatol Rep. 2022. PMID: 35167037 Free PMC article. Review.
35 results